Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Balance | $ 732,667 | $ 597,890 |
| Acquisitions (Note 4) | 136,301 | |
| Currency translation | (4,031) | (1,524) |
| Acquisitions (Note 4) | (326) | |
| Balance | 728,308 | 732,667 |
| Protein Sciences [Member] | ||
| Balance | 377,407 | 347,918 |
| Acquisitions (Note 4) | 30,939 | |
| Currency translation | (4,000) | (1,450) |
| Acquisitions (Note 4) | (326) | |
| Balance | 373,081 | 377,407 |
| Diagnostics and Genomics [Member] | ||
| Balance | 355,260 | 249,972 |
| Acquisitions (Note 4) | 105,362 | |
| Currency translation | (31) | (74) |
| Acquisitions (Note 4) | 0 | |
| Balance | $ 355,229 | $ 355,260 |
| X | ||||||||||
- Definition Amount of increase (decrease) from new acquisitions and adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. No definition available.
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|